{
	"format": "specialist_document",
	"locale": "en",
	"details" : {
		"body" : "\n<div class=\"call-to-action\">\n<p>When treating patients who are taking an SGLT2 inhibitor (canagliflozin, dapagliflozin or empagliflozin):</p>\n\n<ul>\n  <li>test for raised ketones in patients with symptoms of diabetic ketoacidosis (<abbr title=\"diabetic ketoacidosis\">DKA</abbr>); omitting this test could delay diagnosis of <abbr title=\"diabetic ketoacidosis\">DKA</abbr></li>\n  <li>if you suspect <abbr title=\"diabetic ketoacidosis\">DKA</abbr>, stop SGLT2 inhibitor treatment  </li>\n  <li>if <abbr title=\"diabetic ketoacidosis\">DKA</abbr> is confirmed, take appropriate measures to correct the <abbr title=\"diabetic ketoacidosis\">DKA</abbr> and to monitor glucose levels </li>\n  <li>inform patients of the symptoms and signs of <abbr title=\"diabetic ketoacidosis\">DKA</abbr> (see below); advise them to get immediate medical help if these occur</li>\n  <li>be aware that SGLT2 inhibitors are not approved for treatment of type 1 diabetes</li>\n  <li>please continue to report suspected side effects to SGLT2 inhibitors or any other medicines on a <a rel=\"external\" href=\"https://yellowcard.mhra.gov.uk/\">Yellow Card</a></li>\n</ul>\n</div>\n\n<h2 id=\"reports-of-diabetic-acidosis\">Reports of diabetic acidosis</h2>\n<p>Sodium glucose co-transporter 2 (SGLT2) inhibitors are licensed for use in adults with type 2 diabetes to improve glycaemic control. Serious and life-threatening cases of <abbr title=\"diabetic ketoacidosis\">DKA</abbr> have been reported in patients taking SGLT2 inhibitors (canagliflozin, dapagliflozin or empagliflozin). </p>\n\n<p>In several cases, blood glucose levels were only moderately elevated (eg &lt;14 mmol/L or 250 mg/dL), which is <strong>atypical for <abbr title=\"diabetic ketoacidosis\">DKA</abbr>.</strong> This atypical presentation could delay diagnosis and treatment. Therefore inform patients of the signs and symptoms of <abbr title=\"diabetic ketoacidosis\">DKA</abbr> (eg nausea, vomiting, anorexia, abdominal pain, excessive thirst, difficulty breathing, confusion, unusual fatigue or sleepiness) and test for raised ketones in patients with these signs and symptoms.</p>\n\n<p>Half of the cases occurred during the first 2 months of treatment. Some cases occurred shortly after stopping the SGLT2 inhibitor.</p>\n\n<p>One third of the cases involved off-label use in patients with type 1 diabetes. We remind you that this drug class is <strong>not licensed</strong> for the treatment of type 1 diabetes. </p>\n\n<p>The underlying mechanism for SGLT2 inhibitor-associated <abbr title=\"diabetic ketoacidosis\">DKA</abbr> has not been established. We are investigating this concern along with other EU medicines regulators. We will communicate further advice as appropriate once the investigation is complete.</p>\n\n<h2 id=\"sglt2-inhibitors--medicines-in-this-class\">SGLT2 inhibitors – medicines in this class</h2>\n<p>The SGLT2 inhibitors marketed in the UK are listed below. Click on the brand name to see the summary of product characteristics (<abbr title=\"summary of product characteristics\">SPC</abbr>). </p>\n\n<table>\n  <thead>\n    <tr>\n      <th>Brand name</th>\n      <th>Active substance(s)</th>\n    </tr>\n  </thead>\n  <tbody>\n    <tr>\n      <td><a rel=\"external\" href=\"https://www.medicines.org.uk/emc/medicine/27188\">Forxiga</a>▼</td>\n      <td>Dapagliflozin tablets (5 mg and 10 mg)</td>\n    </tr>\n    <tr>\n      <td><a rel=\"external\" href=\"https://www.medicines.org.uk/emc/medicine/28667\">Xigduo</a>▼</td>\n      <td>Dapagliflozin/metformin tablets (5 mg/850 mg and 5 mg/1000 mg)</td>\n    </tr>\n    <tr>\n      <td><a rel=\"external\" href=\"https://www.medicines.org.uk/emc/search/?q=canagliflozin&amp;dt=1\">Invokana</a>▼</td>\n      <td>Canagliflozin tablets (100 mg and 300 mg)</td>\n    </tr>\n    <tr>\n      <td><a rel=\"external\" href=\"https://www.medicines.org.uk/emc/search/?q=canagliflozin&amp;dt=1\">Vokanamet</a>▼</td>\n      <td>Canagliflozin/metformin tablets (50 mg/850 mg, 50 mg/1000 mg, 150mg/850mg, 150mg/1000mg)</td>\n    </tr>\n    <tr>\n      <td><a rel=\"external\" href=\"https://www.medicines.org.uk/emc/search/?q=Empagliflozin&amp;dt=1\">Jardiance</a>▼</td>\n      <td>Empagliflozin tablets (10 mg and 25 mg)</td>\n    </tr>\n  </tbody>\n</table>\n\n<h2 id=\"further-information\">Further information</h2>\n<p><a rel=\"external\" href=\"http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/referrals/SGLT2_inhibitors/human_referral_prac_000052.jsp&amp;mid=WC0b01ac05805c516f\">European Medicines Agency announcement</a> June 2015</p>\n\n<p>Post-publication addition: <a rel=\"external\" href=\"https://assets.digital.cabinet-office.gov.uk/media/559d1b6f40f0b6156400002f/SGLT2_inhibitors_DHPC_sent_July_2015.pdf\">letter sent to health professionals</a> in July 2015</p>\n\n<p>Article citation: Drug Safety Update Volume 8 issue 11 June 2015 1.</p>\n",
		"metadata": {
			"bulk_published" : false,
			"therapeutic_area" : [
				"endocrinology-diabetology-metabolism"
			],
			"document_type" : "drug_safety_update"
		},
		"headers" : [
			{
				"text" : "Reports of diabetic acidosis",
				"level" : 2,
				"id" : "reports-of-diabetic-acidosis"
			},
			{
				"text" : "SGLT2 inhibitors – medicines in this class",
				"level" : 2,
				"id" : "sglt2-inhibitors--medicines-in-this-class"
			},
			{
				"text" : "Further information",
				"level" : 2,
				"id" : "further-information"
			}
		],
		"change_history" : [
			{
				"note" : "First published.",
				"public_timestamp" : "2015-06-26T10:20:12+00:00"
			}
		]
	},
	"base_path" : "/drug-safety-update/sglt2-inhibitors-canagliflozin-dapagliflozin-empagliflozin-risk-of-diabetic-ketoacidosis",
	"description" : "Test for raised ketones in patients with acidosis symptoms, even if plasma glucose levels are near-normal.",
	"title" : "SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis",
	"public_updated_at" : "2015-07-08T14:08:17+00:00"
}
